A Miss for Novel Autism Drug

By |2022-07-25T10:21:53-07:00July 21st, 2022|Brief Bulletins from the Field, We Know Psychiatry|

Balovaptan, a novel drug that binds to and blocks vasopressin 1A (V1a) receptors, does not improve social communication in children and adolescents with autism spectrum disorder (ASD), new research shows. Efficacy analysis from a phase 2 trial included more than 160 participants, making it the largest of its kind to date, investigators note. Although [...]

Latest Research on Cannabis and Cannabidiols: Autism, Stress Anxiety and Depression

By |2019-03-28T18:53:46-07:00April 30th, 2018|Featured, We Know Psychiatry|

Autism Researchers at University of California San Diego School of Medicine are preparing a first-of-its-kind, multidisciplinary investigation to determine if and how cannabidiol (CBD), a non-psychoactive compound found in the cannabis plant, provides therapeutic benefit to children with severe symptoms of autism spectrum disorder (ASD). The study, scheduled to launch [...]

Anxiety and Depression May be Prevalent in Children with Comorbid Autism and ADHD

By |2018-04-19T09:16:58-07:00April 16th, 2018|We Know Psychiatry|

Children with comorbid autism spectrum disorder (ASD) and attention-deficit/hyperactivity disorder (ADHD) are at an increased risk of anxiety and mood disorders, a cross-sectional analysis has shown. “Our study supports that anxiety and mood disorders, although highly prevalent in those with ASD alone, are even more prevalent in individuals who have [...]

Folic acid and multivitamin supplements associated with reduced autism risk

By |2018-01-08T09:06:52-08:00January 8th, 2018|Brief Bulletins from the Field, We Know Psychiatry|

Taking folic acid and/or multivitamin supplements preceding and during pregnancy is associated with a lower risk of offspring developing autism spectrum disorder (ASD), an observational epidemiologic study published Jan. 3 showed. The findings could have important public health implications, reported Stephen Z. Levine, PhD, and his associates. The case-cohort study included [...]

Diuretic Continues to Show Promise in Autism

By |2021-11-11T17:13:58-08:00March 23rd, 2017|Brief Bulletins from the Field, We Know Psychiatry|

Treatment with the diuretic bumetanide (Bumex, Validus) improved core symptoms of autism spectrum disorder (ASD), including social deficits and stereotyped behaviors, results from a multicenter phase 2b study show. Bumetanide was effective in improving ASD-related symptoms across the pediatric age range, as assessed by the Childhood Autism Rating Scale (CARS), [...]

The US Preventive Services Task Force Recommendation on Screening for Autism Spectrum Disorder

By |2016-02-17T00:55:49-08:00February 17th, 2016|We Know Psychiatry|

The US Preventive Services Task Force Recommendation on Screening for Autism Spectrum Disorder Michael Silverstein, MD, MPH; Jenny Radesky, MD In this issue of JAMA, the US Preventive Services Task Force (USPSTF) presents final recommendations for screening children aged 18 to 30 months for autism spectrum disorder (ASD).1 Autism spectrum disorder can be responsible [...]

Decreased Brain Levels of Vitamin B12 in Aging, Autism and Schizophrenia

By |2016-01-23T17:51:42-08:00January 23rd, 2016|We Know Psychiatry|

Abstract Many studies indicate a crucial role for the vitamin B12 and folate-dependent enzyme methionine synthase (MS) in brain development and function, but vitamin B12 status in the brain across the lifespan has not been previously investigated. Vitamin B12 (cobalamin, Cbl) exists in multiple forms, including methylcobalamin (MeCbl) and adenosylcobalamin [...]

Title

Go to Top